Kudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu Yun et al.
IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bev in a global phase 3 study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 538-538
Kudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu-Yun et al.
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 studyLIVER CANCER. 2023
Vithayathil, Mathew; D'Alessio, Antonio; Fulgenzi, Claudia Angela Maria et al.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinomaHEPATOLOGY INTERNATIONAL. Bd. 17. H. 4. 2023 S. 904-914
Michel, Maurice; Doll, Michelle; Armandi, Angelo et al.
Impairment of health-related quality of life among people with type 2 diabetes and advanced fibrosisJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S618-S619
Dietz-Fricke, Christopher; Tacke, Frank; Zoellner, Caroline et al.
Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic responseJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S1139-S1140
Schneider, Paul; Capeloa, Leon; Zhang, Heyang et al.
In vivo cancer-associated fibroblast specific gene silencing for anti-stromal therapy in primary liver cancer using novel siRNA loaded polypeptoide nanoparticlesJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S28-S29
Lam, Lyn Ley; Pavlakis, Nick; Shitara, Kohei et al.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)BMC CANCER. Bd. 23. H. 1. 2023
Wagner, Anna Dorothea; Grabsch, Heike I.; Mauer, Murielle et al.
Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer groupJOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Teufel, Andreas; Geier, Andreas; Sarrazin, Christoph et al.
Intersectoral management of patients with abnormal liver enzymes and non-alcoholic fatty liver disease (NAFLD)ZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 61. H. 08. 2023 S. 1028-1036
Teufel, Andreas; Geier, Andreas; Sarrazin, Christoph et al.
Intersectoral management of patients with abnormal liver enzymes and non-alcoholic fatty liver disease (NAFLD)ZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 61. H. 08. 2023 S. 1028-1036